4.5 Article

The Protein Synthesis Inhibitors Mycalamides A and E have Limited Susceptibility Toward the Drug Efflux Network

Journal

JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
Volume 26, Issue 3, Pages 94-100

Publisher

WILEY-BLACKWELL
DOI: 10.1002/jbt.20414

Keywords

Mycalamide; Efflux; PDR; Resistance

Funding

  1. Victoria University of Wellington
  2. New Zealand Agency for International Development

Ask authors/readers for more resources

The mycalamides belong to a family of protein synthesis inhibitors noted for antifungal, antitumour, antiviral, immunosuppressive, and nematocidal activities. Here we report a systematic analysis of the role of drug efflux pumps in mycalamide resistance and the first isolation of mycalamide E. In human cell lines, neither P-glycoprotein overexpression nor the use of efflux pump inhibitors significantly modulated mycalamide A toxicity in the systems tested. In Saccharomyces cerevisiae, it appears that mycalamide A is subject to efflux by the principle mediator of xenobiotic efflux, Pdr5p along with the major facilitator superfamily pump Tpo1p. Mycalamide E showed a similar efflux profile. These results suggest that future drugs based on the mycalamides are likely to be valuable in situations where efflux pump-based resistance leads to failure of other chemotherapeutic approaches, although efflux may be a mediator of resistance in antifungal applications. (c) 2012 Wiley Periodicals, Inc. J Biochem Mol Toxicol 26:94-100, 2012; View this article online at wileyonlinelibrary.com. DOI 10:1002/jbt.20414

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available